Skip to main content
Evotec SE logo

Evotec SE — Investor Relations & Filings

Ticker · EVT ISIN · DE0005664809 LEI · 529900F9KI6OYITO9B12 F Professional, scientific and technical activities
Open in API
Filings indexed 1,778 across all filing types
Latest filing 2012-10-08 Regulatory Filings
Country DE Germany
Listing F EVT

About Evotec SE

https://www.evotec.com/en

Evotec SE is a life science company focused on drug discovery and development in partnership with pharmaceutical and biotechnology firms. The company operates an integrated research and development value chain, utilizing proprietary technology platforms that incorporate AI-driven innovation and induced pluripotent stem cells (iPSC). Its expertise spans a wide range of therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics division, the company offers end-to-end solutions for the design, development, and manufacturing of biologic therapies, aiming to enhance their accessibility and affordability. Evotec employs flexible partnering models to accelerate the delivery of new treatments to patients with high efficiency and quality.

Recent filings

Filing Released Lang Actions
Evotec receives Milestone in Drug Discovery Collaboration
Regulatory Filings Classification · 96% confidence The document is a short press release dated October 8, 2012, announcing that Evotec AG received a pre-clinical milestone payment from a collaboration with Novartis. It details the terms of the collaboration, including potential future payments and royalties. This type of announcement, which is not a full financial report (like 10-K or IR), a management change (MANG), or a dividend notice (DIV), falls under general corporate news regarding business development and potential future revenue streams. Since it is a specific announcement about a business event (milestone achievement in a drug discovery collaboration) and does not fit the definitions for ER, CT, CAP, or LTR, the most appropriate classification is the general regulatory/corporate announcement fallback, RNS, as it is disseminated via DGAP (a service for Regulatory Announcements, Financial/Corporate News and Press Releases). It is too specific for RNS if a better fit existed, but given the options, RNS serves as the best fit for a non-standard corporate news release.
2012-10-08 English
Evotec AG: Corporate Update
Board/Management Information Classification · 99% confidence The document is a short corporate announcement dated October 4, 2012, titled 'Evotec AG: Corporate Update'. The content details a temporary leave of absence for the CEO, Dr. Werner Lanthaler, due to health reasons and names the interim leadership team (Dr. Cord Dohrmann, Colin Bond, and Dr. Mario Polywka). This announcement concerns changes in senior management personnel. According to the definitions, 'Board/Management Information (Code: MANG)' covers the 'Announcement of changes in the company's board of directors or senior management.' The document is short and functions as a direct announcement, not a comprehensive report, making MANG the most appropriate classification.
2012-10-04 English
Investor Presentation 2012
Investor Presentation Classification · 99% confidence The document contains detailed financial projections (tables with Revenues, EBITDA, EPS, margins), investment recommendations ('Recommendation: BUY'), price targets, and extensive disclaimers typical of equity research reports, specifically mentioning German regulatory requirements (§ 34b WpHG, FinAnV). It analyzes a specific company (Evotec AG) and provides forward-looking analysis, which aligns best with an Investor Presentation (IP) or a detailed research report. Since it is a comprehensive analysis with financial tables and recommendations, it is classified as an Investor Presentation (IP) or a detailed research document, rather than a brief Earnings Release (ER) or a formal regulatory filing like 10-K. Given the structure, it strongly resembles an equity research report, which often overlaps with Investor Presentations in format when distributed externally. However, among the provided codes, 'IP' (Investor Presentation) is the closest fit for detailed, non-regulatory, forward-looking analysis distributed by a research firm, although 'MDA' (Management Reports) or 'AR' (Audit Report/Information) could also be considered if it were a company-issued document. Since this is clearly produced by 'Close Brothers Seydler Research AG', it is a research report. In the absence of a specific 'Equity Research Report' code, 'IP' (Investor Presentation) is often used for detailed, non-earnings-release research documents containing forecasts and recommendations, or 'RPA' if it were just announcing the release. Given the content is the analysis itself, 'IP' is the most appropriate choice for a detailed, non-statutory analysis document.
2012-10-02 English
Evotec and Bayer enter into multi-target alliance to fight Endometriosis
Regulatory Filings Classification · 100% confidence The document is a press release dated October 1, 2012, announcing a multi-year collaboration and licensing agreement between Evotec AG and Bayer Pharma AG regarding the development of drug candidates for endometriosis. It details financial terms (upfront payment, milestones, royalties) and strategic rationale. This type of announcement, detailing a significant business development, partnership, or financing activity, aligns best with the 'Capital/Financing Update' (CAP) category, although it is primarily a strategic alliance. Since there is no specific code for 'Strategic Alliance' or 'Partnership Announcement', and it involves significant financial commitments and future revenue potential, it is closest to CAP. However, given the nature of the announcement (a corporate development news release distributed via DGAP), and lacking specific financial structure changes like debt issuance or equity offering, it is often classified as a general Regulatory Filing (RNS) if a more specific category doesn't fit perfectly. Looking at the definitions, 'CAP' covers 'fundraising, financing activities, or capital structure changes.' This is a collaboration, not direct financing. 'LTR' is for legal proceedings. 'RPA' is for announcing the publication of other reports. Since this is a direct announcement of a major corporate event (a partnership), and it doesn't fit the other specific financial/governance/legal codes, the most appropriate general category for significant, non-standard corporate news distributed via regulatory channels is RNS (Regulatory Filings/General Regulatory Announcements). Given the high-level nature of the news (a major drug development alliance), RNS is the safest fallback for significant corporate news not covered elsewhere.
2012-10-01 English
Evotec and Bayer enter into multi-target alliance to fight endometriosis
M&A Activity Classification · 99% confidence The document is an 'Ad-hoc' announcement dated October 1, 2012, detailing a new 'multi-target alliance' between Evotec and Bayer for drug development. This announcement describes a significant business transaction involving collaboration, upfront payments, and potential future milestones. This type of strategic business development or partnership announcement, which is material information disclosed outside of standard periodic financial reports, best fits the category for M&A Activity (TAR) if it involves a major transaction, or potentially Regulatory Filings (RNS) if it's a general disclosure. Since the core event is a major strategic alliance/collaboration that involves significant financial terms (EUR 12 million upfront, potential EUR 580 million milestones), it strongly relates to corporate transactions. However, none of the definitions perfectly capture a strategic R&D alliance. Given the options, 'M&A Activity (TAR)' is the closest fit for a major corporate transaction/deal, although 'Regulatory Filings (RNS)' is a strong fallback for material, non-standard disclosures. Since this is a specific business deal announcement, TAR is chosen over the general RNS fallback, as it signals a major corporate action.
2012-10-01 English
Evotec and Aspireo enter into strategic advisory agreement
Regulatory Filings Classification · 100% confidence The document is a press release dated September 28, 2012, announcing a 'strategic advisory agreement' between Evotec AG and Aspireo Pharmaceuticals regarding the development and partnering of a drug candidate (Somatoprim). This type of announcement, detailing a business development, alliance, or partnership, does not fit the specific categories like 10-K (Annual Report), ER (Earnings Release), or CT (Call Transcript). It is a corporate news item concerning business strategy and potential future financing/partnering, but it is not explicitly a Capital/Financing Update (CAP) or M&A Activity (TAR). Since it is a general corporate announcement disseminated via a news service (DGAP), and it doesn't fit the highly specific financial reporting or event categories, the most appropriate general classification is Regulatory Filings (RNS), which serves as the fallback for miscellaneous corporate news that doesn't fit elsewhere, although it strongly resembles a general press release about a strategic alliance.
2012-09-28 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.